Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 10, 2007

GSK Puts Down $6M for Phase I Trial Initiation of Targacept’s Pain Candidate

  • Targacept initiated a Phase I trial of TC-6499, triggering a $6 million milestone payment from GlaxoSmithKline (GSK). This early-stage small molecule is being  initially developed as a treatment for neuropathic pain.

    In July, GSK and Targacept entered a partnership worth over $1.5 billion for novel therapeutics that selectively target specified neuronal nicotinic receptors (NNRs). The advancement of TC-6499 marks the first reported milestone. Targacept is eligible to receive an additional milestone fee if the company determines to advance TC-6499 into Phase II.

    TC-6499 was discovered using Targacept’s drug design technology known as Pentad™. “TC-6499 represents the third Pentad-enabled product candidate that we have advanced into the clinic this year, demonstrating the strength of Pentad, our ability to execute our operating plans successfully, and the breadth and pharmacological diversity of our pipeline of NNR Therapeutics,” comments J. Donald deBethizy, Ph.D., Targacept’s president and CEO.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »